Bone mineral density in children and adolescents with perinatal HIV infection

AIDS

Volumn 27, Issue 2, 2013, Pages 211-220

  DiMeglio, Linda A ^a   Wang, Jiajia ^b   Siberry, George K ^c   Miller, Tracie L ^d   Geffner, Mitchell E ^e   Hazra, Rohan ^c   Borkowsky, William ^f   Chen, Janet S ^g   Dooley, Laurie ^h   Patel, Kunjal ⁱ   Van Dyke, Russell B ^j   Fielding, Roger A ^k   Gurmu, Yared ⁱ   Jacobson, Denise L ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^j TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^k TUFTS UNIVERSITY   (United States)

more..

Author keywords

antiretroviral agents; bone age; bone mineral density; CD4; children; HIV; viral load

Indexed keywords

CALCIUM; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; VITAMIN D; ZIDOVUDINE;

ADOLESCENT; ADULTHOOD; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE AGE; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIETARY INTAKE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GROUPS BY AGE; GROWTH ACCELERATION; GROWTH DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PERINATAL INFECTION; PHYSICAL ACTIVITY; PREDICTIVE VALUE; PREPUBERTY; PREVALENCE; PRIORITY JOURNAL; PUBERTY; PUERTO RICO; SCHOOL CHILD; UNITED STATES; VIRUS LOAD;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; GROWTH; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MALE; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; VIRAL LOAD;

EID: 84872397733     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835a9b80     Document Type: Article

References (34)

1. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med 2010; 61:169-185.
2. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174.
3. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937-946.
4. Paccou J, Viget N, Legrout-Gerot I, Yazdanpanah Y, Cortet B. Bone loss in patients with HIV infection. Joint Bone Spine 2009; 76:637-641.
5. McKay H, Bailey D, Mirwald R, Davison K, Faulkner R. Peak bone mineral accrual and age at menarche in adolescent girls: a 6-year longitudinal study. J Pediatr 1998; 133:682-687.
6. Jacobson DL, Lindsey JC, Gordon CM, Moye J, Hardin DS, Mulligan K, et al. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS 2010; 24:687-696.
7. Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, et al. Peak bone mass. Osteoporos Int 2000; 11:985-1009.
8. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
9. Fakruddin JM, Laurence J. Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis. Clin Exp Immunol 2004; 137:538-545.
10. Gibellini D, De CE, Ponti C, Cimatti L, Borderi M, Tschon M, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008; 80:1507-1514.
11. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23:1519-1529.
12. CDC United States Growth Charts In: www.cdc.gov/growth charts. 2000 [Accessed on 7 January 2011].
13. Jacobson DL, Patel K, Siberry GK, Van Dyke RB, DiMeglio LA, Geffner ME, et al. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pedia-tric HIV/AIDS Cohort Study. Am J Clin Nutr 2011; 94:1485-1495.
14. Caldwell MB, Oxtoby MJ, Simonds RJ, Lindegren ML, Rogers MF. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR CDC Surveill Summ 1994; 43:1-10.
15. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. Stanford, CA: Stanford University Press; 1959.
16. Ellis KJ, Shypailo RJ. Body composition comparison data for children. See: http://www.bcm.edu/bodycomplab/Applica tions/zscrmainpage.htm. 2000 [Accessed on 31 May 2011].
17. Frost HM. Bone 'mass' and the 'mechanostat': a proposal. Anat Rec 1987; 219:1-9.
18. Bolland MJ, Grey AB, Gamble GD, Reid IR. Clinical Review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 2007; 92:4522-4528.
19. Hui SL, DiMeglio LA, Longcope C, Peacock M, McClintock R, Perkins AJ, et al. Difference in bone mass between black and white American children: attributable to body build, sex hormone levels, or bone turnover? J Clin Endocrinol Metab 2003; 88:642-649.
20. Rauch F, Plotkin H, DiMeglio L, Engelbert RH, Henderson RC, Munns C, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions. J Clin Densitom 2008; 11:22-28.
21. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS 2012; 26:285-293.
22. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011; 6:e17217.
23. Prior J, Burdge D, Maan E, Milner R, Hankins C, Klein M, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 2007; 18:1345-1353.
24. Siberry GK, Li H, Jacobson D. Fracture risk by HIV infection status in perinatally HIV-exposed children. AIDS Res Hum Retroviruses 2012; 28:247-250.
25. Tsekes G, Chrysos G, Douskas G, Paraskeva D, Mangafas N, Giannakopoulos D, et al. Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. HIV Med 2002; 3:85-90.
26. van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, et al. First line zidovudine/lamivu-dine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23:1367-1376.
27. Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 2002; 277:19247-19250.
28. Silva CC, Goldberg TB, Teixeira AS, Dalmas JC. The impact of different types of physical activity on total and regional bone mineral density in young Brazilian athletes. J Sports Sci 2011; 29:227-234.
29. Panel on Antiretroviral Therapy and Medical Management of HIV-infected Children Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. See: http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. 2011. 1-268. [Accessed on 12 July 2011].
30. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008; 152:582-584.
31. Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, et al. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A 2010; 107:13848-13853.
32. Yin MT, McMahon DJ, Ferris DC, Zhang CA, Shu A, Staron R, et al. Low bone mass and high bone turnover in postmenopau-sal human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2010; 95:620-629.
33. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-1068.
34. Zamboni G, Antoniazzi F, Bertoldo F, Lauriola S, Antozzi L, Tato L. Altered bone metabolism in children infected with human immunodeficiency virus. Acta Paediatr 2003; 92:12-16.